Product Introduction

Glycomet Trio 1/0.3 mg Tablet is a combination oral anti-diabetic medicine that helps manage type 2 diabetes mellitus in adults. It contains **Glimepiride**, **Metformin**, and **Voglibose**, which work together to control blood glucose levels through different mechanisms. This medicine is prescribed when diet, exercise, and single-agent therapy fail to control blood sugar adequately.

It is recommended to take this tablet with food to minimize gastrointestinal side effects and avoid hypoglycemia. Regular monitoring of blood glucose is important to evaluate the effectiveness of therapy and avoid complications.

Uses of Glycomet Trio Tablet

• Management of Type 2 Diabetes Mellitus

Benefits of This Medicine

By combining three anti-diabetic agents, Glycomet Trio improves insulin action, reduces glucose production in the liver, and delays glucose absorption from the intestine. This leads to more stable and sustained blood sugar control, helping prevent long-term complications such as kidney damage, nerve problems, and heart disease.

Possible Side Effects

Most side effects are mild and temporary, but if they persist or become bothersome, consult your doctor.

• Flatulence or bloating
• Stomach pain or discomfort
• Diarrhea
• Metallic taste
• Low blood sugar (especially if meals are skipped)
• Dizziness or weakness

How to Use

Take the medicine exactly as prescribed by your physician. Swallow it whole with water, preferably after meals. Do not crush or chew. Follow your diabetes meal plan and activity schedule for optimal results.

How It Works

Glycomet Trio combines three active agents:

• Glimepiride: Stimulates the pancreas to release insulin.
• Metformin: Lowers glucose production by the liver and improves insulin sensitivity.
• Voglibose: Slows carbohydrate digestion and glucose absorption in the intestine.

This combination targets fasting as well as post-meal sugar spikes, offering broad glycemic control.

Frequently Asked Questions (FAQs)

References:
Glimepiride – NCBI
Metformin – NCBI
Voglibose pharmacology – PubMed
WHO Global Diabetes Guidelines